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Edited by Robert BaroukiAbstract The oxidoreductase ERp57 is involved in the forma-
tion and breaking of disulﬁde bonds in assembling proteins within
the environment of the endoplasmic reticulum. Site-directed mu-
tants of the redox-active Cys-Gly-His-Cys motif within an iso-
lated ERp57 sub-domain have been studied. Whereas mutation
of either cysteine residue abolished reductase activity, substitu-
tion of the central residues resulted in retention of partial activ-
ity. Alkylation studies indicated that the central residue mutants
retained the normal disulﬁde bond in the motif, whereas this
disulﬁde bond became more resistant to reduction following addi-
tion of a third residue into the redox motif, demonstrating an
optimum spacing within the redox-active motif of ERp57.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The folding of many proteins is dependent on correct disul-
ﬁde bond formation [1]. Members of the thioredoxin super-
family can carry out disulﬁde bond oxidation, reduction and
isomerisation, with important members located in the endo-
plasmic reticulum (ER), including protein disulﬁde isomerase
(PDI) and its close relative ERp57 [2,3].
Members of the thioredoxin family possess at least one do-
main containing the redox-active motif CXXC, where XX rep-
resents two other amino acids [3]. ERp57 has two such
domains, both containing the redox motif Cys-Gly-His-Cys
(CGHC). The two domains containing the active sites motifs
(denoted a and a 0) are located at either end of ERp57, sepa-
rated by two non-catalytic domains (b and b 0), which in addi-
tion to a tail domain gives the multi-domain order abb 0a 0c.
Whereas the b 0 and a 0 domains appear important in the inter-
action of PDI with its substrates, in the case of ERp57 multiple
domains including the abb 0 domains are necessary for its inter-
action with the P-domain of calreticulin [4]. Mutation of the
cysteine residues is known to inhibit the reductase activity of
ERp57 [5,6]. The importance of the CXXC motif is further
demonstrated in yeast where a PDI homologue, Eug1p, nor-
mally contains the motif CXXS, and has low reductase and*Corresponding author.
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tion of the redox motifs to CXXC [7]. Furthermore in yeast the
presence of multiple homologues of PDI have been shown to
have essentially non-interchangeable functions [8].
Mutation of the central XX residues of the CXXC motif of
this superfamily appears to alter the redox potential and en-
zyme activity [9]. For example, altering the CGPC of thiore-
doxin to CGHC of PDI leads to an increase in redox
potential and an enzyme which is less reducing and more oxi-
dising compared to wildtype [10,11]. More recently, it has also
been shown that the presence of a conserved arginine residue
in the locality of the redox motifs is crucial to the catalytic
function of PDI, and dramatically inﬂuences the pKa of the ac-
tive site cysteines [12].
ERp57 also plays an important role in the immune system. It
is found in association with folding major histocompatibility
complex (MHC) class I molecules and as part of the peptide-
loading complex (PLC) in the ER, which comprises MHC class
I molecules, calreticulin, ERp57, the class I-speciﬁc accessory
molecule tapasin, and the cytosol-to-ER peptide transporter
TAP [13–15]. In ERp57-deﬁcient cells MHC class I molecules
are not stably integrated into the PLC [16], however, the pre-
cise role of ERp57 in MHC class I assembly remains somewhat
unclear. Disulﬁde bond intermediates of the MHC class I hea-
vy chain with ERp57 can be detected [6,17], indicating its di-
rect involvement in the folding process. Somewhat
unexpectedly it has become evident that in the PLC ERp57
is primarily disulﬁde linked to an unpaired cysteine residue
in tapasin through the redox motif in the ERp57 a domain
[18,19]. The reason for this linkage is not known, but may sug-
gest that tapasin and ERp57 act in combination in the optimi-
sation of the peptide pool to be loaded into the groove of
MHC class I molecules. It has also recently been shown that
the disulﬁde linkage to tapasin inhibits the escape pathway
that normally acts to release oxidoreductases from their sub-
strate polypeptides [20].
The relative importance of the two central residues in the
CXXC motif of ERp57 has not been investigated. Because
the a domain of ERp57 is disulﬁde linked to tapasin in the
PLC we have studied the a 0 domain and its redox motif, rea-
soning that it might be accessible to possibly inﬂuence the
disulﬁde status of MHC class I molecules within the PLC.
Our results demonstrate that alteration of these residues in
an isolated, functional domain has deleterious eﬀects on the
reductase activity, as does the addition of a third residue be-
tween the two cysteines.blished by Elsevier B.V. All rights reserved.
Fig. 1. Puriﬁcation and reductase activity of the ERp57 a 0c domain.
(A) Domain organisation of ERp57 and the a 0c fragment. (B)
Recombinant ERp57 and a 0c were aﬃnity puriﬁed from bacterial
lysates, and analysed by SDS–PAGE and Coomassie Blue staining. (C)
Recombinant ERp57 and a 0c were incubated in the presence of insulin
and a ﬁnal DTT concentration of 0.32 mM. The control sample
(Negative) included insulin and DTT alone.
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2.1. Site-directed mutagenesis
The N-terminally HIS-tagged a 0c domain of rat ERp57, contained in
the pET15b plasmid vector was subjected to site-directed mutagenesis
using Quickchange (Stratagene) methodology, utilising the following
primers (and their complementary sequences), with mutations under-
lined. SGHC (C405S): 5 0-ttttatgctccttggtctggccactgtaagaacctggaaccc-
3 0; CGHS (C408S): 5 0-ttttatgctccttggtgtggccactctaagaacctggaaccc-3 0;
CAHC (G406A): 5 0-ttttatgctccttggtgtgcccactgtaagaacctggaaccc-30;
CGAC (H407A): 5 0-ttttatgctccttggtgtggcgcctgtaagaacctggaaccc-30;
CAAC (G406A/H407A): 5 0-ttttatgctccttggtgtgccgcctgtaagaacctg-
gaaccc-3 0; CGDC (H407D): 5 0-ttttatgctccttggtgtggcgactgtaagaacctg-
gaaccc-3 0; CGHAC: 5 0-ttttatgctccttggtgtggccacgcctgtaagaacctggaaccc-
3 0.
PCR products were transformed into XL10 Gold and DNA from
expanded colonies was sequenced to conﬁrm mutagenesis.
2.2. Bacterial expression of mutant A 0C domains
Mutant DNA was transformed into BL21 cells and LB broth cul-
tures induced for 1 h with 1 mM IPTG. SDS–PAGE of whole cell ly-
sates was used to conﬁrm protein expression. Solubility of expressed
mutants was tested using BPER (Perbio) as per manufacturers instruc-
tions. For large-scale puriﬁcation 100 ml overnight cultures were in-
duced with IPTG as above and cell pellets resuspended in 10 ml
BPER. Post-centrifugation supernatants were passed over Ni-agarose,
washed, and the histidine-tag removed from the recombinant proteins
by cleavage with 5 U thrombin for 2 h at room temperature. Superna-
tants were dialysed against 25 mMHEPES overnight and samples con-
centrated and stored at 80 C.
2.3. Insulin precipitation assay
Freshly dissolved insulin (Sigma) at 1 mg/ml was stored on ice in as-
say buﬀer (100 mM KAc, pH 7.5, 2 mM EDTA). 50 ll of insulin was
added to a microcuvette at room temperature. ERp57, a 0c or mutants
were added in 10 ll assay buﬀer to give a ﬁnal assay concentration of
1 lM. 2 ll of 10 mM DTT was then added, gently mixed and the opti-
cal density at 650 nm measured every minute.
2.4. Alkylation of CXXC motifs
One microgram of a 0c and mutants were made up to 10 ll with
50 mM HEPES (pH 7.5) in triplicate. 0.5 ll of 1 mM DTT was added
to the third tube of each set. All samples were incubated at 37 C for
10 min. Non-reducing sample buﬀer with or without 0.3 mM 4 0-
maleimidylstilbene-2,2-disulphonic acid (AMS, Molecular Probes,
The Netherlands) was added as required. Samples were incubated at
room temperature for 20 min, then analysed by SDS–PAGE. In exper-
iments where the reoxidation of the CXXC motif was studied 0.5 lg of
a 0c and CGHAC polypeptides in 10 ll 50 mM HEPES were supple-
mented with 5 ll of the reducing agent Tris(2-carboxyethyl) phosphine
hydrochloride (TCEP) immobilised on agarose beads (approximately
8 lmol/ml, Perbio) for 45 min at 37 C. The TCEP-beads were then
pelleted by brief centrifugation and the supernatant removed and
either immediately subjected to AMS alkylation in non-reducing sam-
ple buﬀer, or incubated at room temperature for a further 45 min be-
fore AMS alkylation and SDS–PAGE analysis.Table 1
Summary and nomenclature of the mutations in the a 0c domain
fragment of ERp57 used in this study
Mutant
number
Mutation Mutant name
1 C405S SGHC
2 C408S CGHS
3 G406A CAHC
4 H407A CGAC
5 G406A/H407A CAAC
6 H407D CGDC
7 Insertion of A between H407/C408 CGHAC3. Results
3.1. Reductase activity of isolated a 0c domain of ERp57
ERp57 contains redox CGHC motifs in both the a and a 0
domains (Fig. 1A). In order to analyse the eﬀects of mutation
on a single CGHC motif, the a 0c domain was expressed and
examined in isolation. Bacterially expressed and aﬃnity puri-
ﬁed full length ERp57 and the a 0c domain (Fig. 1B) were com-
pared for reductase activity in an insulin precipitation assay
[5]. The a 0c domain retained signiﬁcant activity in comparison
to full length ERp57 (Fig. 1C), validating its use as a target for
mutational analyses.3.2. Reductase activity of a 0c redox motif mutant molecules
Site-directed mutagenesis was performed on the a 0c domain
to generate mutants of the four residues in the CGHC motif.
Additionally, a mutant was generated such as to add a third
residue in between the two cysteine residues, resulting in the
motif CGHAC. The full list of the 7 mutants generated is given
in Table 1. All the mutants were successfully aﬃnity puriﬁed
from the soluble fraction of bacterial lysate preparations,
and their purity assessed by non-reducing SDS–PAGE analysis
(Fig. 2A). In the case of mutant CGHS, and less so in the case
of mutant SGHC, a band of approximately 40000 molecular
mass was detected in several puriﬁcation preparations. Upon
analysis in reducing conditions this band disappeared, suggest-
ing that it was a dimer of the a 0c domain induced by the un-
paired cysteine in these mutants.
Insulin precipitation assays were performed to determine the
reductase activity of the a 0c mutants. The assays were repeated
four times overall, from two separate puriﬁcations, with a
reproducible pattern of results. Mutants from which the cys-
teine residues were removed (SGHC and CGHS) were both
Fig. 2. Puriﬁcation and reductase activity of A 0C domain redox motif mutants. (A) Bacterial expressed and aﬃnity puriﬁed recombinant a 0c domain
mutants were analysed under non-reducing conditions by SDS–PAGE. (B) a 0c domain and cysteine-mutants were incubated with insulin and DTT as
in Fig. 1. Negative control was insulin and DTT alone. (C) a 0c redox motif central residue mutants were tested for reductase activity against insulin.
Negative samples were run at the start (1) and the end (2) of the assay, comprising insulin and DTT alone. The percent ﬁnal reductase activity of two
further experiments using the mutants is shown in the two panels.
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two residues were altered all retained partial activity
(Fig. 2C). Notably, mutant CGDC, where the positive charge
of the histidine was replaced with the negatively charged aspar-
tic acid, was the most active of the alterations, whereas in mu-
tant CAHC, replacement of the glycine residue resulted in
considerable impairment of activity. In all the assays mutant
CGHAC, where an additional third residue was present be-
tween the cysteines, produced no activity.
3.3. Accessibility of cysteines to alkylation in redox motif
mutants
In puriﬁed recombinant form it was anticipated that the cyste-
ines of the a 0c domain exist as an oxidised disulﬁde pair. To
determine if the alterations in reductase activity observed in
the redox motif mutants in Fig. 2 were due to changes in the sta-
tus of the disulﬁde pair, we undertook experiments to evaluate ifthe cysteines were paired or unpaired in the mutants. We made
use of 4 0-maleimidylstilbene-2,2-disulphonic acid (AMS), which
alkylates free cysteines, and with a molecular mass of 536.44 al-
lows the detection of modiﬁed cysteines by an increase in size of
the target polypeptide on SDS–PAGE.Wildtype andmutant a 0c
preparations were incubated in the presence or absence of DTT
at 48 lM (the latter to fully reduce any disulﬁde pair), andmod-
iﬁed with AMS. As shown in Fig. 3A, both cysteine mutants
SGHC and CGHS undergo minor increases in size indicating
the modiﬁcation of the single available cysteine. Of note,
DTT-sensitive dimers of SGHCandCGHSwere detected in this
experiment. All the mutants with modiﬁcations to their central
two residues required the presence of DTT to achieve AMS
alkylation (indicated by an asterisk). Thus under the conditions
in which these polypeptide have been puriﬁed from bacterial cell
lysates the cysteines in these mutants appear to be disulﬁde
paired.
Fig. 3. Alkylation of a 0c domain redox motif mutants. (A) Recombinant a 0c samples were incubated for 10 min at 37 C with or without DTT
(48 lM ﬁnal concentration), before addition of sample buﬀer containing the alkylating agent AMS, and analysis by SDS–PAGE. An asterisk
indicates the AMS-modiﬁed product. (B) Mutant CGHAC was incubated with the indicated levels of DTT prior to AMS alkylation. (C) Mutant
CGHAC was tested at 37 C in the insulin precipitation assay, and the optical density read after 60 min. Samples were: A, insulin at room
temperature; B, insulin and DTT at room temperature; C, insulin at 37 C; D, insulin and DTT at 37 C; E, a 0c domain and insulin and DTT at
37 C; F, mutant CGHAC and insulin and DTT at 37 C. (D) Disulﬁde bond formation after removal of reducing agent. a 0c and CGHAC were
alkylated with AMS in the absence of reducing agent (lanes 1 and 4), or incubated with TCEP-agarose beads at 37 C and immediately treated with
AMS (lanes 2 and 5) or reincubated at room temperature before addition of AMS (lanes 3 and 6).
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pattern to theothermutants. Its ability tobe alkylatedwas inves-
tigated further using increased concentrations ofDTT.CGHAC
required more DTT to observe reduction, with AMS modiﬁca-
tion occurring at DTT concentrations of 170 lM and above
(Fig. 3B). To further study the ability of mutant CGHAC to
act as a reductase we also determined its activity at 37 C in
the insulin precipitation assay (Fig. 3C). However, although
the increased temperature led to an increase inwildtype a 0c activ-
ity (column E), as shown by comparing the optical density read-
ings in Figs. 2 and 3, mutant CGHAC activity (column F) did
not increase markedly above that of the relevant control sample
(column D), indicating its inability to act as an eﬃcient reduc-
tase. A possibility to account for the failure of CGHAC to act
as a reductase is the inability to complete the escape pathway
due to spatial restraints imposed by the additional residue. This
was examined by inducing reduction with an immobilised agent
(TCEP), and analysing AMS alkylation following reincubating
of the protein after removal of the reduction agent. As shown in
Fig. 3D a 0c was able to reform the disulﬁde in the CXXCmotif,
although in some experiments only approximately 50% became
refractory to AMS alkylation (data not shown). In contrast mu-
tantCGHACdisplayed no loss ofAMSalkylation after removal
of the reducing agent.4. Discussion
Previously we have shown that an ERp57 mutant containing
only themoreN-terminal cysteines of the twoCXXCmotifs, i.e.,
mutant (CGHS)2, was partially active as a reductase, while the
corresponding mutant, (SGHC)2 with only the more C-terminal
cysteines, was inactive [6]. The NMR structure of the PDI a do-
main indicates that it is the N-terminal cysteine which is more
solvent exposed and therefore able to interact with free cysteines
[21]. Thismayaccount for the inactivity ofERp57 (SGHC)2, and
also that of the a 0c mutant SGHC observed in this study
(Fig. 2B). For PDI, (CGHS)2 mutants accumulate as enzyme–
substrate intermediates because the C-terminal residues are usu-
ally required to perform the escape pathway to release the inter-
mediate form [22], which may account for the partial reductase
activity of ERp57 (CGHS)2 [6]. It was therefore unexpected in
this study that mutant CGHS was inactive as a reductase
(Fig. 2B). A possible explanation may be that the a and a 0 do-
mains are not functionally equivalent, comparable to the diﬀer-
ences in function of the corresponding domains of PDI [23,24],
although recent data indicates that the two redox motifs in
ERp57 have very similar redox potentials and that the isolated
domains can act similarly in RNAase refolding [4,25]. Alterna-
tively, it is possible that the absence of a cysteine in the CXXC
S.M. Beynon-Jones et al. / FEBS Letters 580 (2006) 1897–1902 1901motif may lead to an instability of the a 0c domain, as seen for the
a 0 domain of PDI [26], and that the presence of the non-catalytic
b 0 domain may be additionally required.
In PDI [27], and in bacterial DsbA [28], histidine is the second
central residue, providing a positive charge to stabilise ionisa-
tion of theN-terminal cysteine. Interestingly, replacing histidine
with the negative charge of aspartate produced a mutant
(CGDC) with more reductase activity than a simple alanine
replacement (CGAC). This indicates that the charge status of
this residue is not crucial for maintaining reductase activity,
and that in fact the size of the residue in this second position
may be more important. Alternatively the aspartate may also
contribute to the stabilisation of the reduced motif, which could
be tested in the future with further mutants such as CGEC or
CGNC. The absence of a glycine residue next to the histidine
(CAHC) also proved detrimental to reductase activity, possibly
by restricting conformations that could be adopted in the active
site. However, changing both central residues to alanine
(CAAC) may relax constraints induced by the alanine–histidine
pair, leading to the increase in reductase activity we observed.
Overall, small conformational changes that may have been in-
duced by the central residue mutations may have contributed
to a stabilisation of the reduced form of a 0c, similar to observa-
tions made in the thioredoxin active site [29]. Nevertheless, in
puriﬁed recombinant form, the cysteines appeared to be in a
disulﬁde pair in the absence of a reducing agent (Fig. 3). It should
be noted that this situation diﬀers from the status of ERp57
in vivo where it appears to exist mostly, excluding its interaction
with tapasin, in reduced form [18,30].
Mutant CGHAC was virtually inactive as a reductase. It was
anticipated that this was due to inhibition of disulﬁde bond
formation caused by the extra residue. However, the cysteines
proved inaccessible to AMS modiﬁcation unless exposed to in-
creased DTT concentrations. This unexpected result suggested
that CGHAC formed a more stable disulﬁde bond in compar-
ison to a 0c. Incubation at 37 C did not restore CGHAC reduc-
tase activity. Furthermore removal of reducing agent failed to
allow reformation of the disulﬁde, which in contrast did occur
for a 0c. Our data suggests that once the more stable disulﬁde
bond in CGHAC has been broken it is unable to reform, mak-
ing this mutant inactive.
The ability tomodify the behaviour of individual redoxmotifs
within ERp57, as demonstrated here, may allow further analysis
of the MHC class I peptide-loading complex. We have studied
the a 0c domain here because it is most likely to be available for
substrate interactions when part of the PLC. Thus, it is the a 0 do-
main thatmay potentially be relevant to controlling the disulﬁde
status ofMHCclass Imolecules.Wehave demonstrated here the
ability tomodify the activity of ERp57. By introducing suchmu-
tants intoERp57 deﬁcient cells [16] wemay be able to discern the
role of ERp57 within the peptide-loading complex.
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